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CHANges IN THe sAfeTy PRofIle of oRAl DIABeTes MeDICATIoNs 
APPRoveD By THe fDA
Al-Mutairi R., Seoane-Vazquez E.
MCPHS University, Boston, MA, USA
OBJECTIVES: The increase in the prevalence of type-2 diabetes has resulted in a 
substantial increase in the utilization of oral diabetes drugs in the US. This study 
assessed changes in the safety profile of the oral diabetes medications approved by 
the US Food and Drug Administration (FDA) as of December 31, 2014. METHODS: 
Regulatory information for oral diabetes medications as of December 31 was derived 
from the FDA webpage. Label information was extracted from the FDA webpage 
and paper copies of the PDR Book. Drugs were classified according to the WHO 
anatomical therapeutic chemical classification. Descriptive statistics and chi-square 
tests were used for the analysis. RESULTS: The FDA listed a total of 44 oral diabetes 
medications as of December 31, 2014, including 30 single active ingredients and 
14 fixed-dose combinations. Three of the single active ingredients and 1 of the 
combinations were discontinued from the market as of December 31, 2014. In total, 
15.9% of the drugs were approved before 1990, 22.7% in the 1990s, 36.4% in the 2000s, 
and 25.0% in 2010-2014. The main changes in safety profile of the drugs included 
in the study occurred in contraindications (changes in 50.0% of the drugs), limita-
tions (38.6%), warning and precautions (36.4%), and black box warnings (20.5%). 
Additionally, changes also occurred in the indications approved by the FDA for 31.8% 
of the drugs. Changes in safety profile did not significantly varied according to the 
year of approval of a drug; however, drugs approved in the period 2010-2014 had 
a lower number of safety changes due to the limited time these drugs have been 
in the market. CONCLUSIONS: This study found substantial changes over time in 
the safety profile of oral diabetes drugs. Future research should evaluate the effect 
of changes in the safety profile of oral diabetes medication on patient outcomes.
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OBJECTIVES: Despite being the most efficacious blood glucose lowering therapy, 
the majority of patients on basal insulin do not achieve adequate glycemic control 
(HbA1c< 7.0%), increasing the risk of complications. A patient-adjusted mealtime 
insulin-dosing algorithm was recently validated in a randomized clinical trial 
(AUTONOMY) and demonstrated statistically significant and clinically meaningful 
reductions in HbA1c (-1.0%). The goal of our study was to estimate the longer term 
economic outcomes of this clinical trial treatment effect in a representative sample 
of US patients with Type 2 diabetes. METHODS: We utilized a validated Monte Carlo 
microsimulation model to compare patients initiating the AUTONOMY daily (Q1D) 
titration algorithm upon HbA1c drift to those delaying initiation. Outcomes mod-
eled included mean HbA1c, diabetes-related complications, mortality, and associ-
ated costs over 10 years. Treatment effects were modeled from AUTONOMY clinical 
trial results. The setting for the economic analysis was representative of the care 
delivered within the general population of patients utilizing insulin within the US 
(NHANES). Sensitivity analyses included factors such as time horizon, discount 
rate, and baseline HbA1c. RESULTS: Patients initiating self-adjusted bolus titra-
tion upon HbA1c drift had better outcomes over the 10 years: decreases of -1.3% in 
severe hypoglycemic events, -2.8% in myocardial infarction or cardiac events, -1.8% 
in stroke, -6.9% in blindness, -12.4% in lower extremity amputations, and -1.7% in 
mortality. These patients were estimated to have a small increase in pharmacy 
BACKGROUND: Chronic kidney disease (CKD) is highly prevalent in type 2 diabetes 
mellitus (T2DM) population. However, information regarding recent temporal trends 
and prevalence within key demographic subgroups are lacking. OBJECTIVES: To 
estimate the prevalence of CKD stages in T2DM over time and within demographic 
subgroups. METHODS: Individuals ≥ 18 years old with T2DM were identified from 
the US National Health and Nutrition Examination Survey (NHANES) 2007-2012 via 
either self-reported diabetes or antidiabetic medication use. Individuals with type 
1 diabetes, pregnancy, and with missing serum creatinine lab value, age, gender, or 
race were excluded. CKD was staged based on KDIGO 2012 guidelines as: 1= esti-
mated glomerular filtration rate (eGFR in ml/min/1.73m2 via CKD-Epi equation) ≥ 90 
with albuminuria; 2= 60-89 with albuminuria; 3a= 45-59; G3b= 30-44; 4= 15-29; 5= < 15. 
Projected national estimates are reported using appropriate NHANES weights to 
account for non-response bias and oversampling. RESULTS: Of the 2,006 T2DM indi-
viduals, the overall age-adjusted CKD prevalence from 2007-2012 was 38.3%: 40.2% 
in 2007-2008, 36.9% in 2009-2010, and 37.6% in 2011-2012. Most CKD patients were at 
early stages (77.5% for Stages 1 to 3a), with only 22.5% with moderate to severe CKD 
(Stages 3b to 5). Over the 3 survey cycles, the prevalence of Stage 3a increased while 
Stage 1 and 2 decreased. The prevalence of CKD in patients with T2DM was 25.7% 
in < 65 years old, 58.7% in ≥ 65 years old, 40.0% in males, 38.7% in females, 43.5% 
in both Blacks and Mexican Americans, and 38.7% in Whites. CONCLUSIONS: Our 
findings, in this nationally representative population, highlight that CKD, primarily 
early stages, is prevalent among a large group of T2DM patients, particularly Blacks 
and Mexican-Americans, for whom interventions may be targeted in order to slow 
and/or prevent the progression of kidney function decline. Patients not aggres-
sively targeted for CKD screening, such as younger patients, also warrant attention.
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OBJECTIVES: This study compared hypoglycemia rates in patients with type 2 dia-
betes on metformin who augmented treatment with saxagliptin or glipizide 5-20 
mg/day. METHODS: This retrospective analysis utilized US healthcare claims data 
from the Truven Health MarketScan Research Databases. Data were from adults on 
metformin monotherapy who added saxagliptin or glipizide 5-20 mg/day between 
1 August 2009 and 31 December 2010. Hypoglycemia event rates were compared 
during the 4 months after initiation of saxagliptin or glipizide. A hypoglycemia 
event was defined as a diagnosis of hypoglycemia on an outpatient or emergency 
room claim, a principal diagnosis on a hospital claim, or a glucagon injection 
in an outpatient setting. Analyses were adjusted for patient demographics and 
clinical characteristics using inverse propensity score weights and rate ratios 
were computed using bivariate Poisson regression. To achieve maximal covariate 
balance in adjusted analyses, only patients with a propensity score ≥ 0.02 were 
retained for analysis. RESULTS: A total of 9,246 patients (1,567 taking saxagliptin; 
7,679 taking glipizide) qualified. During 120 days of follow-up, there were 205 
hypoglycemia events. Most of the hypoglycemia events (93.2%) occurred in the 
outpatient setting. There were no inpatient or emergency room hypoglycemia 
events in the saxagliptin cohort. The overall unadjusted rate of hypoglycemia was 
significantly lower in the saxagliptin cohort than in the glipizide cohort (1.74 vs. 
7.73 per 100 person-years; p< 0.001; rate ratio= 0.23 [95% confidence interval= 0.10-
0.44]). After applying inverse propensity score weights (N= 8,241), the adjusted rate 
of hypoglycemia also was significantly lower in the saxagliptin cohort versus the 
glipizide cohort (1.74 vs. 4.18 per 100 person-years; p= 0.002; rate ratio= 0.42 [95% 
confidence interval= 0.24-0.71]). CONCLUSIONS: Treatment with saxagliptin was 
associated with a lower risk of hypoglycemia compared with glipizide 5-20 mg/
day in a real-world database. These results add confidence to similar findings 
from clinical trials.
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OBJECTIVES: Diabetes influences bone metabolism, but the relation of type 1 diabe-
tes mellitus (T1DM) with bone mineral density (BMD) remains inconsistent across 
studies. The objective of this study was to perform a meta-analysis to estimate 
the difference in BMD between T1DM and non-diabetic populations. METHODS: 
Studies were selected by doing comprehensive literature search in PubMed and 
EMBASE up to January 2014. Additional searches were also conducted to include 
research abstracts, cross references and bibliography of individual articles. All stud-
ies, including cross-sectional, cohort or case–control design, showing association 
between T1DM and BMD measured by dual energy X-ray absorptiometry (DEXA) 
were considered eligible for the review. A random effects meta-analysis was per-
formed. Heterogeneity and publication bias were checked. Results are expressed as 
Pearson correlations. RESULTS: The analysis was done on 48 observational studies 
reporting 2,885 cases and 4,814 controls. Meta-analysis showed that BMD in T1DM 
patients was significantly lower, with pooled mean differences of -0.43 (95% CI: 
-0.69, -0.17) in women and -0.25 (95% CI: -0.50, -0.005) in men at the hip region. It 
was also found significantly lower at the spine region [-0.30 (95% CI: -0.47, -0.13)] in 
men and forearm region [-0.21 (95% CI: -0.43, 0.00)] in women. No siginificant differ-
ence was found in BMD (in both men and women) between in case of femoral neck 
region. Sensitivity analysis confirmed the stability of our results. CONCLUSIONS: 
Our analysis confirmed that both men and women with T1DM have preponderence 
to have lower BMD levels. Multiple factors (age/gender/menopausal status/bone 
type) can inﬂuence BMD in individuals with T1DM. Large prospective epidemiologi-
cal studies are required to confirm our findings.
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life-year (QALY) gain among T2DM patients treated with dapa vs. other antidiabetic 
drugs. Changes in clinical endpoints, including HbA1c, weight, systolic blood pressure 
(SBP), and hypoglycemia risk, associated with 52-week treatment with the different 
antidiabetic drugs were obtained from a network meta-analysis. Annual medical 
costs and QALYs for changes in clinical endpoints were obtained from published 
literature. RESULTS: For one year of treatment of a T2DM patient, medical costs 
associated with changes in HbA1c, weight, SBP, and hypoglycemia risk for dapa were 
-$173 (Confidence interval: -$1,125, $747) vs. GLP-1 agonists, -$1,061 (-$1,859, -$362) 
vs. DPP-4 inhibitors, -$1,524 (-$2,552, -$649) vs. TZDs, and -$2,300 (-$3,131, -$1,574) 
vs. SUs. Results from univariate and multivariable sensitivity analyses showed that 
the estimates of the medical cost differences were most affected by variations in 
weight and SBP changes, but were generally robust when model parameters were 
varied. Treatment with dapa was cost saving vs. other antidiabetic drugs when only 
medical costs were considered. When drug costs were included, treatment with dapa 
remained either cost saving (vs. GLP-1 agonists and DPP-4 inhibitors) or cost-effective 
vs. TZDs ($10,007 per QALY), vs. SUs ($9,650 per QALY). CONCLUSIONS: Treatment of 
T2DM patients with dapa was associated with reduced medical costs vs. daily dosage 
GLP-1 agonists, DPP-4 inhibitors, TZDs, and SUs. When drug costs were included, treat-
ment with dapa was cost saving vs. daily dosage GLP-1 agonists and DPP-4 inhibitors 
and cost-effective vs. TZDs and SUs.
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TyPe 2 DIABeTes MellITus IN INDIA
Hussain S., Kumari S.
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OBJECTIVES: To compute the cost of medicines used in the treatment of T2DM and 
study the variation in the costs. METHODS: Indian Council of Medical Research 
(ICMR) and International Diabetes Federation (IDF) guidelines were used to under-
stand the treatment of T2DM. Current Index of Medical Specialities (CIMS) Apr-
July2014 issue and Indian Drug Review (IDR) issue 2, Feb2014 were used to capture 
the prices of medicines available in the Indian market. The annual cost of treatment 
and variation in the annual cost of drugs was studied. RESULTS: IDF recommends 
first line treatment with metformin 500mg twice a day. The annual cost of treat-
ment with metformin was found to be Rs.467-2336. A variation of 400% is noted 
in the least-highest cost of metformin. Glimepiride 2mg OD is used as a second 
line treatment and its annual cost ranges between Rs.458-4851. It shows maxi-
mum variation of 960% in the least-highest cost. Likewise, third line treatment can 
be started either with α -Glucosidase inhibitor or DPP4 inhibitor or Thiazolidine 
group of drugs. Annual cost of treatment with Pioglitazone 15mg was found to 
be Rs.365-2555. Among the third line category of drugs, Pioglitazone 15mg shows 
maximum variation of 600% in the least-highest cost. Used as a fixed dose combina-
tion (FDC), Glimepiride+Metformin (1+500 mg) showed maximum price variation of 
529%. CONCLUSIONS: It was concluded that a maximum of 11 fold variation was 
observed in the least-highest costs of treatment with Glimepiride 2mg in the year 
2014. Wide variation exists in the percentage price variation of same drug manu-
factured across the different brands.
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OBJECTIVES: To assess economic burden and quality of life (QoL) associated with 
acromegaly in the United States. METHODS: A web-based cross-sectional sur-
vey was conducted from August –October, 2014. Patient-reported information on 
acromegaly-related economic burden was collected. The direct and indirect costs 
per patient over the past 3 months included out-of-pocket cost, sick leave, leave of 
absence, direct loss of job due to acromegaly, unemployment, assistance to perform 
household chores, and family member loss of income. The QoL was assessed by 
Acromegaly Quality of Life (AcroQoL) and EQ-5D questionnaires. Descriptive analysis 
was used. RESULTS: A total of 106 patients completed the survey (mean age: 46 
years, female: 76%). The annualized office visits per person to physicians, nurses 
and other health professionals was 11.8, 3.4 and 6.6 visits, respectively. The acro-
megaly patients had 0.7 emergency room visits, 0.3 hospital admissions and length 
of hospital stay of 1.8 days. Annualized healthcare out-of pocket cost was $1,790/
person. The average number of days unable to work was 34 days with estimated 
income loss $6,702 /person-year. The average annual loss of income due to direct 
loss of job, unemployment disability, household chores, and income loss of family 
members was $6,106, $10,653, $1,685, and $472/person, respectively. As compared 
with low-symptom group, symptom 0-3 (n= 41), the high-symptom group with 4+ 
symptoms (n= 65) had significantly higher costs by category (loss of job: $8,876 
vs. $1,717, p= 0.017; unemployment disability: $17,102 vs. $429, p= 0.003; house-
hold chores: $540 vs. $233, p= 0.0003; family members’ loss: $128 vs. $23, p= 0.028). 
The average EQ-5D index score and global score of AcroQoL were 0.62±0.23 and 
38.61±22.39, respectively. Patients reporting 4 + symptoms had lower QoL scores as 
compared with those with fewer symptoms (EQ-5D: 0.53 vs. 0.75, p< 0.0001; AcroQoL: 
27.38 vs. 56.43, p< 0.0001). CONCLUSIONS: Patients with acromegaly experienced 
high economic burden and poor quality of life.
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OBJECTIVES: Type 2 diabetes mellitus (T2DM) is a prevalent disease affecting over 
25 million people in the United States. Diabetes inflicts a heavy economic burden 
costs ($347) due to longer lifetimes, and had a direct medical cost reduction (-$1,716) 
due to improved glycemic control. CONCLUSIONS: The AUTONOMY Q1D titration 
algorithm offers a simple and effective approach to assist patients requiring basal-
bolus therapy in adjusting their meal-time insulin dose. Results from our study 
indicate that compared to published delays in treatment modification or escalation, 
an adaptive daily titration algorithm can lead to better outcomes at lower costs.
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OBJECTIVES: The IDF global guideline for type-2 DM considers metformin as first-
line therapy, without contraindications, but gastrointestinal intolerance occurs in 
20-30% of patients receiving an immediate release of metformin, being a possible 
barrier to treatment adherence. Glucophage® XR is an extended-release formulation 
of metformin IR, with the same antidiabetic efficacy, a flexible dosing range to assist in 
treatment titration with superior gastrointestinal tolerability, contributing to greater 
compliance. The aim of this study is to evaluate the cost-effectiveness (CE) and budget 
impact (BI) of metformin XR compared to metformin IR, in adults with type-2 DM, 
from the perspective of the public health system in Brazil. METHODS: The outcomes 
of interest were days on treatment; number of events (stroke, myocardial infarc-
tion, heart failure, peripheral mononeuropathy, retinopathy, blindness, diabetic foot, 
amputation, diabetic nephropathy and renal disease); number of full-lifetime-patients 
without treatment (non-compliance); number of full-lifetime-patients with controlled 
diabetes; and life years. Efficacy data were obtained from literature review and unit 
costs were obtained from official price lists. The time horizon of the CE and BI model 
was 30 and 10 years respectively. A 5% annual discount rate was applied to costs and 
benefits in the CE model. RESULTS: Glucophage® XR increased overall survival in 0.75 
day and assured more 1,631 days on treatment, per patient, during lifetime period. 
Also, reduced 6,249 events and allowed more 143 full-lifetime-patients with controlled 
type-2 DM, per 1,000 patients. Glucophage® XR was dominant vs. Metformin IR, result-
ing in saving approximately 5.5% (BRL 10,961,011 per patient). Additionally, the use 
of Glucophage® XR in patients with type-2 DM resulted in saving of approximately 
BRL 3,787,758,740.88 in the period from 2014 to 2025. CONCLUSIONS: Glucophage® 
XR showed dominance versus metformin IR due to a safer profile leading to better 
tolerance, compliance and better health outcomes.
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OBJECTIVES: To estimate and compare annual direct medical costs associated 
with diabetic complications in patient with type 2 diabetes in the USA and South 
Korea. METHODS: Data were obtained from the 2010-2011 Medical Expenditure 
Panel Survey (MEPS), which is a nationally representative sample of ambulatory 
population in the US, and the 2010-2011 Korea Health Panel (KHP) which contains 
health service use and expenditures for a representative sample of Korea. Using 
ICD-9 CM codes, patients were classified as patients with microvascular complica-
tions only (nephropahty, neuropathy, retinopahty, or peripheral vascular disease), 
macrovascular complications only (cardiovascular disease and cerebrovascular 
disease), both complications, and without complications. Direct medical costs 
included costs associated with hospitalization, outpatient visits, emergency room 
visits, and drugs. To compare costs of diabetic patients with and without complica-
tions, direct medical costs were estimated using the generalized linear model (GLM) 
with log link function and gamma distribution after adjusting for patient charac-
teristics. RESULTS: Among 3,864 and 2,060 patients with diabetes in the US and 
Korea, respectively, 87.0% and 61.9% patients had no complications; 4.5% and 17.7% 
patients had microvascular complications only; 8.3% and 13.6% had macrovascular 
complications only; and 0.2% and 6.8% had both complications. The average annual 
direct medical costs per patient were $8,191 in the US and $1,590(US$1= KRW1,000) 
in Korea. After adjusting for patients’ characteristics, annual direct medical costs 
associated with microvascular complications were 2.36(US) and 2.05(Korea) times 
greater; macrovascular complications were 2.70(US) and 1.76 times(Korea) greater, 
while both complications were 5.66(US) vs. 3.08(Korea) times greater than those 
without complications, respectively. CONCLUSIONS: Direct medical treatment costs 
in patients with diabetic microvascular or macrovascular complications were sig-
nificantly higher than those without diabetes complications, and the magnitudes 
of additional costs are different between US and Korea. Providing proper treatment 
of diabetes to prevent or delay diabetic complications is important to minimize 
treatment costs of diabetes.
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OBJECTIVES: The objective of this study was to evaluate the short-term economic 
impact of treatment of type 2 diabetes (T2DM) patients with dapagliflozin (dapa) 
vs. other antidiabetic drugs, including daily dosage glucagon-like peptide-1 (GLP-1) 
agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, thiazolidinediones (TZDs), and 
sulfonylureas (SUs). METHODS: An economic model (1-year time horizon) was devel-
oped to evaluate differences in annual medical costs and costs per quality-adjusted 
